Treace to Highlight Latest Product Innovations and ALIGN3D™ Study Outcomes at the 2024 ACFAS Annual Scientific Conference
Treace Medical Concepts, Inc. announces the full commercial release of its Micro-Lapiplasty™ System and limited clinical release of its Mini-Adductoplasty™ System and RedPoint™ Patient-Specific Instrumentation. The company will highlight new technology innovations and three-year interim ALIGN3D™ clinical results at the 2024 American College of Foot and Ankle Surgeons Annual Scientific Conference.
The announcement from Treace Medical Concepts, Inc. regarding the commercial release of its Micro-Lapiplasty™ System and the limited clinical release of its Mini-Adductoplasty™ System and RedPoint™ Patient-Specific Instrumentation (PSI) represents a significant advancement in the field of foot and ankle surgery. The Micro-Lapiplasty™ System, which allows for a minimally invasive approach to bunion correction, could potentially reduce patient recovery time and surgical complications. This is particularly relevant as the demand for less invasive surgical options is increasing. The Mini-Adductoplasty™ System's smaller incision requirement could also lead to similar benefits, enhancing patient outcomes and possibly reducing hospital stays.
From a clinical perspective, the RedPoint™ PSI technology is noteworthy as it introduces a level of customization in surgical planning that can improve the precision of deformity correction procedures. The ability to tailor surgical guides to the individual patient's anatomy could lead to better alignment and stability post-surgery, which are critical factors in the success of foot and ankle procedures. The expanded SpeedPlate™ Configurations are also set to enhance the versatility of fixation options available to surgeons, potentially improving the efficacy of various fusion procedures.
From a market perspective, Treace's product launches are strategically timed to capture a growing segment within the orthopedic device market. The full commercial release of the Micro-Lapiplasty™ System, coupled with the limited clinical release of the Mini-Adductoplasty™ System and RedPoint™ PSI, positions the company to potentially increase its market share in the coming year. The focus on minimally invasive technology aligns with current industry trends and patient preferences, which could drive adoption rates among surgeons and healthcare facilities.
The presentation of three-year interim ALIGN3D™ clinical results at a major conference such as ACFAS is a strategic move to bolster credibility and showcase long-term benefits of the company's procedures. Evidence-based outcomes are crucial for the adoption of new medical technologies and positive clinical data can significantly influence purchasing decisions of hospitals and clinics. The expanded SpeedPlate™ Configurations expected to be available in the first half of 2024 could further diversify the company's product portfolio and address a broader range of surgical needs.
Investors might view the developments announced by Treace Medical Concepts as an indicator of the company's growth trajectory and innovation pipeline. The launch of new products and the expansion of existing lines could lead to increased revenue streams. Moreover, the adoption of these technologies in surgical practices hinges on their ability to demonstrate cost-effectiveness and improved patient outcomes compared to traditional methods. If Treace's new systems deliver on these aspects, they could see widespread uptake, positively impacting the company's financial performance.
However, it is important to consider the costs associated with the development, marketing and distribution of these new systems. Investors should monitor the company's expenditure on these fronts and weigh them against the potential return on investment. The market's response to the ALIGN3D™ clinical results will also be a critical factor to watch, as it may influence the stock's performance in the short-term. Long-term, sustained adoption and positive post-market studies could further reinforce investor confidence in the company's strategic direction.
02/01/2024 - 07:00 AM
Company Previews New SpeedPlate™ Configurations, Announces Full Commercial Release of its Micro-Lapiplasty™ System and Limited Clinical Release of its Mini-Adductoplasty™ System and RedPoint™ Patient-Specific Instrumentation
PONTE VEDRA, Fla., Feb. 01, 2024 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities through its flagship Lapiplasty ® Adductoplasty ® Annual Scientific Conference
“Our continued strong presence at ACFAS underscores Treace's longstanding commitment to investing in the field of foot and ankle surgery,” said John T. Treace, CEO, Founder and Board Member of Treace. “During this year’s ACFAS conference, we are excited to highlight several new innovations from our robust pipeline of ten focused product launches slated from the second half of 2023 through 2024. We also look forward to sharing compelling three-year data from our ALIGN3D™ study in a podium presentation at ACFAS this Friday.”
Treace will feature its current and next-generation technologies at its ACFAS exhibit booth ® and Adductoplasty® surgeon training events featuring recent innovations, including:
Expanded SpeedPlate™ Configurations: Innovative fixation technology designed to deliver the stability of a titanium locking plate with the speed of insertion and compression of a staple. While broadly applicable across Lapiplasty® and Adductoplasty® procedures today, new SpeedPlate™ implant configurations are designed to expand the versatility of the SpeedPlate™ platform to address a wide range of additional fusion procedures throughout the foot. These new SpeedPlate™ configurations are expected to be available in the first half of 2024.Micro-Lapiplasty™ System: Proprietary, advanced instrumentation designed to enable the patented Lapiplasty® Procedure to be performed through a minimally-invasive 2cm incision utilizing new SpeedPlate™ implant technology for fixation. The Micro-Lapiplasty™ System is now in full commercial release and will be featured in hands-on training workshops at the conference.Mini-Adductoplasty™ System: New, advanced instrumentation designed to allow the Adductoplasty® Midfoot Deformity Correction procedure to be performed through a ~50% smaller incision and leverages SpeedPlate™ implant technology for fixation. The Mini-Adductoplasty™ System is currently in limited clinical release with full commercialization planned in the second half of 2024.RedPoint™ Patient-Specific Instrumentation (PSI): First-to-market technology designed to deliver pre-operative planning and patient-specific guides for surgical correction of foot deformities. RedPoint™ PSI is currently in limited clinical release with full commercialization planned in the second half of 2024.Recently introduced Hammertoe PEEK Fixation System and the LapiTome™ and RazorTome™ single-use osteotomes will also be featured at the conference. More information on Treace’s products can be found at www.lapiplasty.com
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements other than statements of historical fact are forward-looking statements, including, but not limited to, the planned full commercialization of the Company’s Mini-Adductoplasty™ System and RedPoint™ Patient Specific Instrumentation in the second half of 2024. Forward-looking statements are based on management’s current assumptions and expectations of future events and trends, which affect or may affect the Company’s business, strategy, operations or financial performance, and actual results and other events may differ materially from those expressed or implied in such statements due to numerous risks and uncertainties. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Factors that could cause actual results or other events to differ materially from those contemplated in this press release can be found in the Risk Factors section of Treace’s public filings with the Securities and Exchange Commission (SEC), including its Annual Report on Form 10-K for the year ended December 31, 2022, and its subsequent SEC filings. Because forward-looking statements are inherently subject to risks and uncertainties, you should not rely on these forward-looking statements as predictions of future events. These forward-looking statements speak only as of their date and, except to the extent required by law, the Company undertakes no obligation to update these statements, whether as a result of any new information, future developments or otherwise.
Internet Posting of Information
Treace routinely posts information that may be important to investors in the “Investor Relations” www.treace.com
About Treace Medical Concepts
Treace Medical Concepts, Inc. is a medical technology company with the goal of advancing the standard of care for the surgical management of bunion and related midfoot deformities. Bunions are complex 3-dimensional deformities that originate from an unstable joint in the middle of the foot and affect approximately 67 million Americans, of which Treace estimates 1.1 million are annual surgical candidates. Treace has pioneered and patented the Lapiplasty® 3D Bunion Correction® system – a combination of instruments, implants, and surgical methods designed to surgically correct all 3 planes of the bunion deformity and secure the unstable joint, addressing the root cause of the bunion and helping patients get back to their active lifestyles. To further support the needs of bunion patients, Treace has introduced its Adductoplasty® Midfoot Correction System, designed for reproducible surgical correction of the midfoot as well as its Hammertoe PEEK Fixation System designed to address hammertoe, claw toe and mallet toe deformities. The company continues to expand its footprint in the foot and ankle market with the introduction of its SpeedPlate™ Rapid Compression Implants, an innovative fixation platform with broad versatility across Lapiplasty® and Adductoplasty® procedures, as well as other common bone fusion procedures of the foot. For more information, please visit www.treace.com
To learn more about Treace, connect with us on LinkedIn Twitter Facebook Instagram
Contacts:
Treace Medical Concepts, Inc. jddewey@treace.com
What new technology innovations will Treace Medical Concepts, Inc. highlight at the 2024 ACFAS Annual Scientific Conference?
Treace Medical Concepts, Inc. will highlight new technology innovations including Expanded SpeedPlate™ Configurations, Micro-Lapiplasty™ System, Mini-Adductoplasty™ System, and RedPoint™ Patient-Specific Instrumentation.
When will the new SpeedPlate™ configurations be available?
The new SpeedPlate™ configurations are expected to be available in the first half of 2024.
What is the current status of the Mini-Adductoplasty™ System?
The Mini-Adductoplasty™ System is currently in limited clinical release with full commercialization planned in the second half of 2024.
What is the RedPoint™ Patient-Specific Instrumentation (PSI)?
RedPoint™ Patient-Specific Instrumentation (PSI) is first-to-market technology designed to deliver pre-operative planning and patient-specific guides for surgical correction of foot deformities. It is currently in limited clinical release with full commercialization planned in the second half of 2024.
Where can more information on Treace's products be found?
More information on Treace’s products can be found at www.lapiplasty.com.
